ClinicalTrials.Veeva

Menu

The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)

E

ECbiotech Taiwan

Status and phase

Completed
Phase 3

Conditions

Diabetes Mellitus, Type II

Treatments

Drug: Extract of Agaricus blazei Murill

Study type

Interventional

Funder types

Other

Identifiers

NCT00131287
TH-EC-05-01

Details and patient eligibility

About

The purpose of this study is to examine whether the extract of the Agaricus blazei Murill mushroom is effective in the supplementary treatment of type II DM patients.

Full description

The researchers have the animal model that the extract of the Agaricus blazei Murill mushroom is effective in the treatment of type II DM mice conducted on 2002. The dose effects were also found. The researchers conducted the pilot study also showing the same effects in 2003. So the researchers designed this trial. The elixir of the Agaricus blazei Murill mushroom is popular in Taiwan for chronic diseases, such as type II DM.

Sex

All

Ages

20 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Type II DM
  • Age 20-75 years old
  • Treat with Gliclazide and Metformin
  • Signed informed consent

Exclusion criteria

  • GOT/GPT >80/80
  • Creatinine > 2.0
  • Lactating or pregnant women

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems